Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2010 May 5

PMID 20440659

Citations 2

Authors

Aizad Mumtaz

Oliver FitzGerald

Affiliations

Soon will be listed here.

Abstract

Psoriatic disease presents with a complex array of clinical features, including peripheral synovitis and skin psoriasis, but there is also variable involvement of the nail, dactylitis, enthesitis, and spinal disease. Composite assessment of disease activity and response taking into account the impact of the disease as a whole on an individual's health and quality of life is of vital importance. Following an extensive literature review, discussions, and consensus, the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA) published guidelines to help clinicians make treatment decisions. The utility of these guidelines in routine clinical practice is further enhanced by incorporating them into a Composite Psoriatic Disease Activity Index (CPDAI). The potential application of the CPDAI in typical psoriatic disease patients is presented and discussed. Validation and possible modification of a composite disease activity and responder index is currently being undertaken by GRAPPA.

Citing Articles

Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion.

Urruticoechea-Arana A, Alvarez-Vega J, Garcia-Vivar M, Pinto-Tasende J, Garcia de Yebenes M, Carmona L Rheumatol Int. 2024; 44(11):2327-2336.

PMID: 38969942 DOI: 10.1007/s00296-024-05644-y.

Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype?.

Tillett W, McHugh N Curr Rheumatol Rep. 2012; 14(4):334-42.

PMID: 22644331 DOI: 10.1007/s11926-012-0265-3.

References

Clegg D, Reda D, Mejias E, Cannon G, Weisman M, Taylor T . Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39(12):2013-20. DOI: 10.1002/art.1780391210. View

Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H . Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003; 62(2):127-32. PMC: 1754445. DOI: 10.1136/ard.62.2.127. View

Gladman D, Cook R, Schentag C, Feletar M, Inman R, Hitchon C . The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. J Rheumatol. 2004; 31(6):1126-31. View

Gladman D, Mease P, Strand V, Healy P, Helliwell P, FitzGerald O . Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007; 34(5):1167-70. View

Kane D, Stafford L, Bresnihan B, FitzGerald O . A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003; 42(12):1460-8. DOI: 10.1093/rheumatology/keg384. View

Mease P, Antoni C, Gladman D, Taylor W . Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005; 64 Suppl 2:ii49-54. PMC: 1766888. DOI: 10.1136/ard.2004.034165. View

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

Gladman D, Farewell V, Buskila D, Goodman R, Hamilton L, Langevitz P . Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol. 1990; 17(1):62-4. View

Nell-Duxneuner V, Stamm T, Machold K, Pflugbeil S, Aletaha D, Smolen J . Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2009; 69(3):546-9. DOI: 10.1136/ard.2009.117945. View

10.

Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M . International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003; 62(9):817-24. PMC: 1754665. DOI: 10.1136/ard.62.9.817. View

11.

Qureshi A, Dominguez P, Duffin K, Gladman D, Helliwell P, Mease P . Psoriatic arthritis screening tools. J Rheumatol. 2008; 35(7):1423-5. View

12.

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

13.

Ashcroft D, Wan Po A, Williams H, Griffiths C . Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141(2):185-91. DOI: 10.1046/j.1365-2133.1999.02963.x. View

14.

Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

15.

Olivieri I, Barozzi L, Favaro L, Pierro A, De Matteis M, Borghi C . Dactylitis in patients with seronegative spondylarthropathy. Assessment by ultrasonography and magnetic resonance imaging. Arthritis Rheum. 1996; 39(9):1524-8. DOI: 10.1002/art.1780390912. View

16.

Antoni C, Krueger G, de Vlam K, Birbara C, Beutler A, Guzzo C . Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64(8):1150-7. PMC: 1755609. DOI: 10.1136/ard.2004.032268. View

17.

Gladman D, Helliwell P, Mease P, Nash P, Ritchlin C, Taylor W . Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004; 50(1):24-35. DOI: 10.1002/art.11417. View

18.

Healy P, Helliwell P . Measuring dactylitis in clinical trials: which is the best instrument to use?. J Rheumatol. 2007; 34(6):1302-6. View

19.

Healy P, Helliwell P . Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008; 59(5):686-91. DOI: 10.1002/art.23568. View

20.

Gladman D, Brubacher B, Buskila D, Langevitz P, Farewell V . Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Clin Invest Med. 1993; 16(1):1-7. View